Development of an integrated risk stratification model for metastatic medulloblastoma (M2/3) using clinical, radiologic, and molecular variables

TL;DR

This study develops a new risk model for metastatic medulloblastoma using clinical, radiologic, and molecular data to improve treatment strategies for high-risk patients.

Contribution

A novel integrated risk stratification model combining clinical, radiologic, and molecular variables for metastatic medulloblastoma.

Findings

The 5-year event-free survival and overall survival rates were 56.1% and 68.7%, respectively.

Molecular subgrouping, metastatic patterns, and the 'sandwich' strategy were independent prognostic predictors.

The 'sandwich' strategy significantly improved survival outcomes in patients with metastatic medulloblastoma.

Abstract

Approximately 20% of medulloblastoma (MB) patients are diagnosed with metastatic disease and typically exhibit extremely poor clinical outcomes. This study aimed to investigate potential prognostic factors affecting the survival of patients with metastatic MB.

Patients with initial diagnosis of metastatic MB (M2/3) at Beijing Tiantan Hospital were included. Radiological characteristics were discerned through a retrospective review. Overall survival (OS) and event-free survival (EFS) were calculated using the Kaplan-Meier analysis. Multivariable Cox proportional hazards model was employed to identify potential prognostic factors.

This study included 115 patients with M2/3 MB. Group 4 MBs accounted for 59.1% of cases (68/115). Kaplan-Meier analysis indicated that the 5-year EFS and OS rates were 56.1% and 68.7%, respectively. Patients with metastatic Group 3 MB and spinal metastases exhibited dismal outcomes. Postoperative “sandwich” strategy significantly prolonged 5-year EFS and OS rates. Multivariate COX regression models demonstrated that molecular subgrouping, metastatic patterns, and “sandwich” strategy were independent prognostic predictors for both EFS and OS in patients with M2/3 MB.

Our study provides a novel risk stratification model for metastatic medulloblastoma that could potentially facilitate the development of individualized therapeutic strategies for the very high-risk patient population.

Figures